clevudine
"Something here doesn’t compute, and I think it’s VRUS’ outsized claims about Clevudine’s MoA."
I don't have a strong opinion on this and to be sure much of what i know comes from company claims, so i tend to agree with you actually. that said, there is a study out there showing virus remained suppressed 24 weeks off clevudine therapy - something not seen with other nukes. could be a fluke. could be 24 weeks won't equate to truly durable response. but it will be interesting to see results of pharmasett's study
"If Clevudine also had a MoA that was far superior to other second-generation nukes in its ability to clear cccDNA, wouldn’t you expect Clevudine to by the leading second-generation nuke in Korea by a wide margin? I would"
i don't think there is enough data to convince docs of this sustained response w clevudine, but that doesn't mean it doesn't exist. putting myself in the MD's shoes I wouldn't take a pt off therapy unless there was better data on this (or i had a rare sAg conversion), so going by potency and resistance alone baraclude is about as good as it gets
" dual advantages of being marketed by a Korean company "
i've never once factored in the nationality of the company when deciding what drug to prescribe. for all we know BMY has a better korean sales team!
BTW i don't own VRUS - i am jsut marginally interested in clevudine becasue IF durable response can be achieved in even a modest proportion of pts then combination studies with interferon will surely follow in the hope (and likelihood i would think) that such a combination can further improve SVR. OTOH if evolution of therapy is geared more towards suppression of resistance then studies looking at combo with other nukes makes more sense
jmo
News 
Market Data 
Discover 
